|
| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Prostate Cancer
|
NCI
|
5R13CA121807-02
|
|
CSHL Conference on PTEN Pathways
|
STEWART, DAVID
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$7,000
|
|
Prostate Cancer
|
NCI
|
1R01CA116379-01A1
|
|
3-D Transrectal Ultrasound with 2-D Arrays
|
YEN, JESSE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$248,168
|
|
Prostate Cancer
|
NCI
|
5R01CA112310-04
|
|
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
|
ROSNER, MARSHA
|
UNIVERSITY OF CHICAGO
|
IL
|
$297,116
|
|
Prostate Cancer
|
NCI
|
7K99CA125937-02
|
|
Characterization of prostatic stem cells and prostate cancer-initiating cells
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$89,179
|
|
Prostate Cancer
|
NIDDK
|
5R37DK047556-14
|
|
HEPARIN-BINDING EGF-LIKE FACTORS IN PROSTATE GROWTH
|
FREEMAN, MICHAEL
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$361,146
|
|
Prostate Cancer
|
NCI
|
5F31CA113285-04
|
|
Mechanism of ART-27 Function in Prostate Cancer
|
NWACHKWU, JEROME
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$46,864
|
|
Prostate Cancer
|
NIDDK
|
5R37DK051193-13
|
|
Role of U19/Eaf2 in androgen-dependent prostate homeostasis
|
WANG, ZHOU
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$289,685
|
|
Prostate Cancer
|
NCI
|
5R01CA111868-04
|
|
Interactions and Functions of p14ARF in Cancer
|
GJERSET, RUTH
|
SIDNEY KIMMEL CANCER CENTER
|
CA
|
$370,484
|
|
Prostate Cancer
|
NIDDK
|
5R37DK045370-11
|
|
Prevention and Treatment of Impotence
|
LUE, TOM
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$330,824
|
|
Prostate Cancer
|
NCI
|
5R33CA118591-03
|
|
An RNA Sensor for Detection of Circulating Tumor Cells
|
CLAWSON, GARY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$284,503
|
|
Prostate Cancer
|
NCI
|
5F32CA112988-03
|
|
Deciphering Beta-Catenin Contributions in Prostate Cance
|
MULHOLLAND, DAVID
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$48,796
|
|
Prostate Cancer
|
NCI
|
5R01CA120451-02
|
|
Pomegranate for Chemoprevention and Chemotherapy of Prostate Cancer
|
MUKHTAR, HASAN
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$279,300
|
|
Prostate Cancer
|
NCI
|
5R01CA102751-04
|
|
MR Based Molecular Imaging of Prostate Cancer
|
KURHANEWICZ, JOHN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$252,330
|
|
Prostate Cancer
|
NCI
|
5R33CA110518-03
|
|
PSA BASED EARLY DETECTION OF PROSTATE CANCER RECURRENCE
|
TAYLOR, JEREMY
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$319,472
|
|
Prostate Cancer
|
NCI
|
5R01CA116673-02
|
|
Clinical Trial of Selenium and Prostate Biomarkers
|
MARSHALL, JAMES
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$410,787
|
|
Prostate Cancer
|
NCI
|
5R01CA075284-09
|
|
Improved Cryosurgical Destruction of Prostate Cancer
|
BISCHOF, JOHN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$319,374
|
|
Prostate Cancer
|
NCI
|
5R01CA109460-03
|
|
PI3K Pathway in Prostate Tumorigenesis and Angiogenesis
|
JIANG, BING-HUA
|
WEST VIRGINIA UNIVERSITY
|
WV
|
$227,246
|
|
Prostate Cancer
|
NCI
|
5R01CA103943-05
|
|
Role of RNase L in the Biology of Prostate Cancer
|
SILVERMAN, ROBERT
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
OH
|
$297,398
|
|
Prostate Cancer
|
NCI
|
7R01CA104334-05
|
|
PREVENTION OF PROSTATIC CARCINOGENESIS BY ANTIOXIDANTS
|
BOSLAND, MAARTEN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$244,138
|
|
Prostate Cancer
|
NCI
|
5R01CA109147-03
|
|
AR and RUNX2 target genes in prostate cancer
|
COETZEE, GERHARD
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$252,841
|
|
Prostate Cancer
|
NCI
|
5R01CA105125-04
|
|
Ceramide synthase as a therapy target in prostate cancer
|
HAIMOVITZ-FRIEDMAN, ADRIANA
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$319,439
|
|
Prostate Cancer
|
NCI
|
5R21CA118362-02
|
|
Targeting Relaxin Signaling in Prostate Cancer
|
AGOULNIK, ALEXANDER
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$150,000
|
|
Prostate Cancer
|
NCI
|
5R01CA116242-02
|
|
Tea Polyphenols in Chemoprevention of Prostate Cancer
|
HENNING, SUSANNE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$264,195
|
|
Prostate Cancer
|
NCI
|
5R01CA119334-29
|
|
Technetium and Rhenium in Nuclear Medicine
|
JONES, ALUN
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$563,873
|
|
Prostate Cancer
|
NIGMS
|
5R01GM064559-07
|
|
Heterocumulenes in Asymmetric Catalysis
|
LECTKA, THOMAS
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$261,467
|
|
Prostate Cancer
|
NCI
|
5R01CA106826-04
|
|
Developmental Transcription Factors in Prostate Cancer
|
MORENO, CARLOS
|
EMORY UNIVERSITY
|
GA
|
$229,214
|
|
Prostate Cancer
|
NCI
|
5R01CA102537-05
|
|
Role of Cten in Prostate Cancer
|
LO, SU
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$221,769
|
|
Prostate Cancer
|
NCI
|
7R01CA109441-04
|
|
IL-4 and androgen receptor signaling in prostate cancer
|
GAO, ALLEN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$213,141
|
|
Prostate Cancer
|
NCI
|
5R01CA111846-03
|
|
Prx1 in malignant progression of prostate cancer
|
PARK, YOUNG-MEE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$307,083
|
|
Prostate Cancer
|
NCI
|
5R01CA112028-04
|
|
Cell Cycle Variants and Metastatic Prostate Cancer Risk
|
KIBEL, ADAM
|
WASHINGTON UNIVERSITY
|
MO
|
$229,214
|
|
Prostate Cancer
|
NCI
|
5R21CA114547-02
|
|
Intervention to Enhance Quality of Life in Men with PCa: Development and Testing
|
ELLER, LUCILLE
|
RUTGERS THE STATE UNIV OF NJ NEWARK
|
NJ
|
$154,500
|
|
Prostate Cancer
|
NCI
|
5R01CA111421-04
|
|
Apoptosis by FADD in normal and cancerous cells
|
THORBURN, ANDREW
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$288,389
|
|
Prostate Cancer
|
NCI
|
5R01CA105402-05
|
|
Androgen and Growth Factor Signaling in Prostate Cancer
|
WEBER, MICHAEL
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$148,210
|
|
Prostate Cancer
|
NCI
|
5R01CA111891-03
|
|
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
|
LU, QUN
|
EAST CAROLINA UNIVERSITY
|
NC
|
$184,029
|
|
Prostate Cancer
|
NCI
|
5R01CA102074-05
|
|
Androgen Control of TGF-beta signaling
|
DANIELPOUR, DAVID
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$293,511
|
|
Prostate Cancer
|
NCI
|
5R01CA107166-05
|
|
PTEN and Prostate Cancer Progression
|
WU, HONG
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$297,832
|
|
Prostate Cancer
|
NCI
|
5R01CA107039-04
|
|
Rexinoid Synergy in Prostate Cancer Apoptosis
|
DAWSON, MARCIA
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
CA
|
$510,361
|
|
Prostate Cancer
|
NCI
|
5R01CA114060-03
|
|
SELECT Pre-Clinical Trial of Prostate Cancer
|
AHMAD, NIHAL
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$250,774
|
|
Prostate Cancer
|
NCI
|
5R01CA112303-04
|
|
Membrane Microdomains in Prostate Cancer
|
FREEMAN, MICHAEL
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$284,832
|
|
Prostate Cancer
|
NCI
|
5R01CA098513-05
|
|
Prostate Cancer Metastasis Suppressor: Role of RKIP
|
KELLER, EVAN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$237,918
|
|
Prostate Cancer
|
NCI
|
5R01CA058093-15
|
|
Mesenchymal Derived Growth Factors in Prostatic Cancer
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$256,863
|
|
Prostate Cancer
|
NCI
|
5R01CA104035-04
|
|
A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
|
JING, NAIJIE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$280,899
|
|
Prostate Cancer
|
NCI
|
1R01CA131013-01
|
|
Multi-parametric MRI Determination of Prostate Cancer Aggressiveness and Extent
|
METZGER, GREGORY
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$311,293
|
|
Prostate Cancer
|
NCI
|
1R01CA131226-01
|
|
Efficacy and Mechanism of Novel Androgen Receptor Inhibitors
|
DIAMOND, MARC
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$320,241
|
|
Prostate Cancer
|
NCI
|
5R01CA064851-14
|
|
KGF in Prostate Cancer: A Transgenic Animal Model
|
GREENBERG, NORMAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$336,274
|
|
Prostate Cancer
|
NCI
|
5R21CA122693-02
|
|
PET-guided Intervention in Lymphatic Metastasis of Prostate Cancer
|
WU, LILY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$185,400
|
|
Prostate Cancer
|
NCI
|
5R01CA102688-05
|
|
Validation of a New Target for Prostate Cancer Therapy
|
BARON, VERONIQUE
|
SIDNEY KIMMEL CANCER CENTER
|
CA
|
$289,700
|
|
Prostate Cancer
|
NCI
|
5R01CA095739-08
|
|
Store-Operated Calcium Entry and Apoptosis
|
MA, JIANJIE
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
NJ
|
$245,631
|
|
Prostate Cancer
|
NCI
|
1R21CA131754-01
|
|
Decision Making in Patients with Advanced Prostate Cancer
|
JONES, RANDY
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$229,141
|
|
Prostate Cancer
|
NCI
|
5R01CA097543-04
|
|
Metabolism of Vitamin A in the Prostate
|
GUDAS, LORRAINE
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$251,685
|
|
Prostate Cancer
|
NCI
|
1R21CA131774-01
|
|
Small RNA targeted gene activation for the treatment of prostate cancer
|
LI, LONG-CHENG
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$208,238
|
|
Prostate Cancer
|
NCI
|
5R01CA046283-20
|
|
MECHANISMS OF EPITHELIAL CELL TUMORIGENESIS IN THE MOUSE
|
VAN DYKE, TERRY
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$479,600
|
|
Prostate Cancer
|
NCI
|
5R01CA105304-05
|
|
Genomic and proteomic analysis of prostate cancer
|
SADAR, MARIANNE
|
BRITISH COLUMBIA CANCER AGENCY
|
CANADA
|
$209,928
|
|
Prostate Cancer
|
NCI
|
7R01CA118887-03
|
|
Selenium regulates androgen receptor signaling in prostate cancer
|
GAO, ALLEN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$235,778
|
|
Prostate Cancer
|
NCI
|
1R21CA132033-01
|
|
Targeted polymeric nanocarriers for combination therapy of prostate cancer
|
FORREST, MARCUS
|
UNIVERSITY OF KANSAS LAWRENCE
|
KS
|
$164,470
|
|
Prostate Cancer
|
NCI
|
5R01CA116636-03
|
|
Prostate Cancer Chemoprevention by Inositol Hexaphosphate Efficacy and Mechanism
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$261,397
|
|
Prostate Cancer
|
NCI
|
5R21CA121782-02
|
|
Cell-targeting peptide nucleic acids for hormone-refractory prostate cancer
|
BARTON, BEVERLY
|
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
|
NJ
|
$187,200
|
|
Prostate Cancer
|
NIA
|
5R44AG029029-03
|
|
Software for Meta-Analysis of Diagnostic Tests
|
BORENSTEIN, MICHAEL
|
BIOSTATISTICAL PROGRAMMING ASSOC, INC.
|
NJ
|
$474,666
|
|
Prostate Cancer
|
NCI
|
5R01CA103934-03
|
|
MR Diffusion Tensor Imaging of Prostate Cancer
|
VIGNERON, DANIEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$261,115
|
|
Prostate Cancer
|
NCI
|
5R01CA104286-05
|
|
Pure Flavonolignans from S. marianum in Prostate Cancer
|
KROLL, DAVID
|
RESEARCH TRIANGLE INSTITUTE
|
NC
|
$386,258
|
|
Prostate Cancer
|
NCI
|
5R01CA111618-04
|
|
Protocadherin-PC and Prostate Cancer
|
BUTTYAN, RALPH
|
ORDWAY RESEARCH INSTITUTE, INC.
|
NY
|
$275,333
|
|
Prostate Cancer
|
NCI
|
5R01CA109874-04
|
|
Beta1 Integrins and IGF-I Receptor in Prostate Cancer
|
LANGUINO, LUCIA
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$273,876
|
|
Prostate Cancer
|
NCI
|
5R01CA114469-05
|
|
Mechanisms of Chemoprevention by Resveratrol
|
SRIVASTAVA, RAKESH
|
UNIVERSITY OF TEXAS HLTH CTR AT TYLER
|
TX
|
$168,184
|
|
Prostate Cancer
|
NCI
|
7R01CA115717-02
|
|
Modeling androgen-independent prostate cancer in mutant mice
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$305,900
|
|
Prostate Cancer
|
NCI
|
5R01CA102218-05
|
|
TRAIL-induced apoptosis in prostate cancer
|
VOELKEL-JOHNSON, CHRISTINA
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$249,182
|
|
Prostate Cancer
|
NIA
|
7R01AG024278-03
|
|
Genetic Analysis of a Prostate Tumor Suppressor Region
|
MARKER, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$289,683
|
|
Prostate Cancer
|
NCI
|
5R01CA120386-02
|
|
Role of Eaf family proteins in prostate carcinogenesis
|
WANG, ZHOU
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$282,150
|
|
Prostate Cancer
|
NCI
|
2R01CA058073-15A1
|
|
Molecular Mechanisms of Growth Control in Prostate Cancer
|
LIAO, SHUTSUNG
|
UNIVERSITY OF CHICAGO
|
IL
|
$315,168
|
|
Prostate Cancer
|
NCI
|
2R01CA085567-06A2
|
|
The Role of CDK5 in Metastasis
|
NELKIN, BARRY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$350,509
|
|
Prostate Cancer
|
NCI
|
2R01CA089406-07A2
|
|
Regulation of cancer cell-cycle by statins
|
DUTTA, ANINDYA
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$230,751
|
|
Prostate Cancer
|
NCI
|
7R01CA116337-03
|
|
"Molecular Signatures of Lethal and Indolent Prostate Cancer"
|
RUBIN, MARK
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$532,731
|
|
Prostate Cancer
|
NCI
|
1R01CA120921-01A2
|
|
Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases
|
WHANG, YOUNG
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$272,655
|
|
Prostate Cancer
|
NCI
|
5R01CA119168-03
|
|
Internet-Based Education for Prostate Cancer Screening
|
TAYLOR, KATHRYN
|
GEORGETOWN UNIVERSITY
|
DC
|
$363,858
|
|
Prostate Cancer
|
NCI
|
5R01CA113903-04
|
|
Communication and Chemoprevention of Prostate Cancer
|
MEHTA, PARMENDER
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$247,753
|
|
Prostate Cancer
|
NCI
|
5R01CA114281-04
|
|
Redox Effects of Selenium for Prostate Cancer Prevention
|
ZHONG, WEIXIONG
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$272,472
|
|
Prostate Cancer
|
NCI
|
5R01CA076639-11
|
|
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
|
STEARNS, MARK
|
DREXEL UNIVERSITY
|
PA
|
$320,012
|
|
Prostate Cancer
|
NCI
|
5R01CA112663-09
|
|
T-bet and Tumor Immunity
|
GLIMCHER, LAURIE
|
HARVARD UNIVERSITY (SCH OF PUBLIC HLTH)
|
MA
|
$297,397
|
|
Prostate Cancer
|
NIA
|
2R01AG019241-06A2
|
|
Prevention of Alzheimer's Diseae by Vitamin E and Selenium
|
MARKESBERY, WILLIAM
|
UNIVERSITY OF KENTUCKY
|
KY
|
$1,304,793
|
|
Prostate Cancer
|
NCI
|
1R01CA122246-01A2
|
|
Pathogenetics of a Clinically-favorable Prostate Cancer Subtype
|
POLLACK, JONATHAN
|
STANFORD UNIVERSITY
|
CA
|
$206,190
|
|
Prostate Cancer
|
NIEHS
|
1R01ES015584-01A1
|
|
Epigenetic Basis for Prostate Carcinogenesis following Early Estrogenic Exposures
|
PRINS, GAIL
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$504,593
|
|
Prostate Cancer
|
NCI
|
1R01CA122247-01A2
|
|
Targeting DHT Catabolism by AKR1Cs for Prostrate Cancer Prevention and Treatment.
|
STOLZ, ANDREW
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$304,403
|
|
Prostate Cancer
|
NCI
|
2R01CA095045-06
|
|
Vitamin D in Prostate Cancer: Tumor Vasculature Effects
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$270,000
|
|
Prostate Cancer
|
NCI
|
2U01CA098710-05
|
|
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.
|
THUN, MICHAEL
|
AMERICAN CANCER SOCIETY, INC.
|
GA
|
$1,063,219
|
|
Prostate Cancer
|
NCI
|
2U01CA098216-05
|
|
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3
|
RIBOLI, ELIO
|
U OF L IMPERIAL COL OF SCI/TECHNLGY/MED
|
UK
|
$1,299,337
|
|
Prostate Cancer
|
NCI
|
5R01CA113363-04
|
|
Prostate Cancer Prevention by Diallyl Trisulfide
|
SINGH, SHIVENDRA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$276,733
|
|
Prostate Cancer
|
NCI
|
5R01CA118947-03
|
|
Chemopreventive Signaling Mechanisms in Prostate Cancer
|
KONG, AH-NG
|
RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK
|
NJ
|
$260,445
|
|
Prostate Cancer
|
NCI
|
2R01CA097134-06A1
|
|
Repressors in Prostate Cancer
|
ROSENFELD, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$311,178
|
|
Prostate Cancer
|
NIDDK
|
2K24DK062895-06
|
|
Osteoporosis in Older Men and Women
|
GREENSPAN, SUSAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$179,335
|
|
Prostate Cancer
|
NCI
|
1K07CA127214-01A1
|
|
Genetic Susceptibility to Cancers of the Prostate and Urinary Bladder
|
BEEBE-DIMMER, JENNIFER
|
WAYNE STATE UNIVERSITY
|
MI
|
$132,819
|
|
Prostate Cancer
|
NCI
|
5R01CA123063-02
|
|
Glycosaminoglycan-based inhibitors for treatment of prostate cancer
|
LOKESHWAR, VINATA
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$260,623
|
|
Prostate Cancer
|
NCI
|
1R21CA127784-01A1
|
|
"Strength training, Self-efficacy, and Function in Blacks with Prostate Cancer."
|
HURLEY, BERNARD
|
UNIVERSITY OF MARYLAND COLLEGE PK CAMPUS
|
MD
|
$165,375
|
|
Prostate Cancer
|
NCI
|
1R21CA122570-01A2
|
|
Profiling Urine Glycosylation of PSA and other Glyco-Biomarkers in Prostate Cance
|
PANNELL, LEWIS
|
UNIVERSITY OF SOUTH ALABAMA
|
AL
|
$165,375
|
|
Prostate Cancer
|
NCI
|
1R01CA127300-01A1
|
|
New Mice Models for Studies of Androgen Receptor in Prostate Cancer
|
CHANG, CHAWNSHANG
|
UNIVERSITY OF ROCHESTER
|
NY
|
$319,550
|
|
Prostate Cancer
|
NIDDK
|
5R01DK058859-08
|
|
Natural History of Prostatism: The Olmsted County Study
|
ST. SAUVER, JENNIFER
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$548,077
|
|
Prostate Cancer
|
NCI
|
5R01CA087869-08
|
|
Epigenetics, Stem Cells, and Cancer
|
JAENISCH, RUDOLF
|
WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
|
MA
|
$863,846
|
|
Prostate Cancer
|
NCI
|
5R01CA118962-02
|
|
Prevention of Prostate Cancer Progression Using Omega-3 Fatty Acids
|
DE GRAFFENRIED, LINDA
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$249,660
|
|
Prostate Cancer
|
NCI
|
1R21CA127768-01A1
|
|
Long-term prediction of prostate cancer death from kallikreins measured in blood
|
LILJA, HANS
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$309,537
|
|
Prostate Cancer
|
NCI
|
5U01CA086402-09
|
|
San Antonio Center - Biomarkers for Prostate Cancer
|
THOMPSON, IAN
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$905,861
|
|
Prostate Cancer
|
NCI
|
1R01CA127735-01A1
|
|
A Role of Novel Serpin Maspinin Prostate Tumor/Bone Interaction
|
SHENG, SHIJIE
|
WAYNE STATE UNIVERSITY
|
MI
|
$312,288
|
|
Prostate Cancer
|
NCI
|
2R01CA069158-12A1
|
|
TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASIS
|
GUISE, THERESA
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$276,088
|
|
Prostate Cancer
|
NCI
|
5R01CA121459-03
|
|
Role of ATBF1 inactivation in the development and progression of prostate cancer
|
DONG, JIN-TANG
|
EMORY UNIVERSITY
|
GA
|
$263,700
|
|
Prostate Cancer
|
NCCAM
|
5R01AT002890-02
|
|
Novel Herbal Medicine for the Treatment of Prostate Cancer
|
DAMODARAN, CHENDIL
|
UNIVERSITY OF KENTUCKY
|
KY
|
$355,097
|
|
Prostate Cancer
|
NIDDK
|
5R01DK065837-04
|
|
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
|
GUISE, THERESA
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$333,010
|
|
Prostate Cancer
|
NCI
|
5U01CA086323-09
|
|
Development/Clinical Validation Markers for Prostate Ca
|
PARTIN, ALAN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$702,609
|
|
Prostate Cancer
|
NCI
|
1R21CA128352-01A1
|
|
A phase II study of IPI-504 in metastatic hormone refractory prostate cancer
|
OH, WILLIAM
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$268,452
|
|
Prostate Cancer
|
NCI
|
5R01CA111782-04
|
|
Translating Prostate Cancer Gene Expression Subtypes
|
BROOKS, JAMES
|
STANFORD UNIVERSITY
|
CA
|
$262,921
|
|
Prostate Cancer
|
NCI
|
7R01CA115985-04
|
|
Molecular analysis of metastatic prostate cancer in mice
|
SHEN, MICHAEL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$301,498
|
|
Prostate Cancer
|
NCI
|
5R01CA065237-20
|
|
Ternary Complex that Drives T Cell Activation
|
FATHMAN, C
|
STANFORD UNIVERSITY
|
CA
|
$275,622
|
|
Prostate Cancer
|
NIDDK
|
5R01DK054257-10
|
|
Molecular Complementation of Nuclear Receptors
|
KOH, JOHN
|
UNIVERSITY OF DELAWARE
|
DE
|
$265,106
|
|
Prostate Cancer
|
NCI
|
5R01CA059897-15
|
|
METABOLIC IMAGING OF THE PROSTATE USING 3-D MRSI
|
VIGNERON, DANIEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$415,964
|
|
Prostate Cancer
|
NCI
|
5R01CA113996-03
|
|
Integrin alpha6beta4 Signaling in Prostate Carcinoma Growth and Invasion
|
GIANCOTTI, FILIPPO
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$383,595
|
|
Prostate Cancer
|
NCI
|
5R21CA124511-02
|
|
Effect of Dietary Omega-3 Fatty Acid Supplement on Prostate Cancer Metastasis
|
CHEN, YONG
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$177,600
|
|
Prostate Cancer
|
NCI
|
5R01CA101035-05
|
|
TARGETS OF AMINO ACID RESTRICTION IN PROSTATE CANCER
|
MEADOWS, GARY
|
WASHINGTON STATE UNIVERSITY
|
WA
|
$256,811
|
|
Prostate Cancer
|
NCI
|
5R01CA107668-05
|
|
Fish Oil Supplement Prevention of Prostate Cancer
|
CHEN, YONG
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$278,932
|
|
Prostate Cancer
|
NCI
|
5R01CA113392-04
|
|
Bone matrix proteins in prostate cancer progression
|
ROY-BURMAN, PRADIP
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$305,244
|
|
Prostate Cancer
|
NCI
|
5R03CA128086-02
|
|
Epitope Array to Complement PSA Tests for Early Detection of Prostate Cancer
|
ZENG, GANG
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$77,250
|
|
Prostate Cancer
|
NCI
|
5R01CA067044-10
|
|
Genetic Epidemiology of Prostate Cancer
|
WHITTEMORE, ALICE
|
STANFORD UNIVERSITY
|
CA
|
$385,278
|
|
Prostate Cancer
|
NCI
|
5R01CA079903-09
|
|
Zinc Transport Relationships in Prostate Cancer Cells
|
FRANKLIN, RENTY
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$253,449
|
|
Prostate Cancer
|
NCI
|
5R01CA118124-02
|
|
Analysis of Homing Receptors in Prostate Cancer
|
DIMITROFF, CHARLES
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$282,720
|
|
Prostate Cancer
|
NCI
|
1R21CA121586-01A2
|
|
MRI Guided and Tumor Targeted HDR Brachytherapy for Recurrent Prostate Cancer
|
MENARD, CYNTHIA
|
UNIVERSITY HEALTH NETWORK
|
CANADA
|
$123,408
|
|
Prostate Cancer
|
NCI
|
1R43CA132538-01
|
|
Dynamic, Structure Driven Fragment Based Design of Selective Androgen Modulators
|
HAGLER, ARNOLD
|
SHIFA BIOMEDICAL
|
PA
|
$284,480
|
|
Prostate Cancer
|
NCI
|
5R01CA106835-04
|
|
Hypofractionated IMRT for Localized Prostate Cancer
|
RITTER, MARK
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$221,342
|
|
Prostate Cancer
|
NCI
|
5R01CA114575-04
|
|
Androgen signaling and kinase regulation in PCA
|
KUNG, HSING-JIEN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$224,441
|
|
Prostate Cancer
|
NCI
|
1R43CA128144-01A1
|
|
Natural Product Screening for Prostate Cancer Therapeutics Using Gene Expression
|
FELDER, STEPHEN
|
NUVOGEN RESEARCH, LLC
|
AZ
|
$162,191
|
|
Prostate Cancer
|
NCI
|
5R01CA107588-05
|
|
Prevention of Prostate Carcinogenesis in Transgenic Mice
|
FISCHER, SUSAN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$287,059
|
|
Prostate Cancer
|
NCI
|
5R01CA109181-05
|
|
Molecular Targeting of Bcl-xL Pathway in Cancer
|
HALDAR, SUBRATA
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$265,033
|
|
Prostate Cancer
|
NCI
|
1F32CA132358-01
|
|
SIRT1 attenuates beta-catenin mediated tumorigenesis
|
BELL, ERIC
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$44,846
|
|
Prostate Cancer
|
NCI
|
1R41CA130493-01A1
|
|
Immunotherapeutic Approaches to Cancer Treatment
|
ALEXANDER, RICHARD
|
VIROGENOMICS, INC.
|
OR
|
$123,614
|
|
Prostate Cancer
|
NCI
|
5U01CA113913-04
|
|
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
|
SANDA, MARTIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$826,363
|
|
Prostate Cancer
|
NCI
|
5F32CA119636-04
|
|
Roles of Wnt Receptors (Frizzled) in Lung Cancer
|
BRAVO, DAWN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$50,428
|
|
Prostate Cancer
|
NIGMS
|
5R01GM066047-06
|
|
Studies of O-linked Glycosylation
|
BERTOZZI, CAROLYN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$309,389
|
|
Prostate Cancer
|
NCI
|
5R01CA127923-02
|
|
IKK and the control of prostate cancer metastasis
|
KARIN, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$264,195
|
|
Prostate Cancer
|
NCI
|
5R01CA114347-04
|
|
NMR detection of tumor differentiation
|
DELIKATNY, EDWARD
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$237,454
|
|
Prostate Cancer
|
NIDCR
|
5R01DE013158-08
|
|
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK
|
LAZARUS, PHILIP
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$483,110
|
|
Prostate Cancer
|
NCI
|
5R37CA037393-27
|
|
Modulators of Prostate Cancer Metastasis
|
ZETTER, BRUCE
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$421,601
|
|
Prostate Cancer
|
NCI
|
5R01CA102102-04
|
|
BIOSYNTHETIC KEY STEPS OF ANGUCYCLINE ANTITUMOR DRUGS
|
ROHR, JURGEN
|
UNIVERSITY OF KENTUCKY
|
KY
|
$246,853
|
|
Prostate Cancer
|
NCI
|
5R01CA107691-05
|
|
Targets of Vitamin D Receptor Action in Prostate
|
WEIGEL, NANCY
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$292,538
|
|
Prostate Cancer
|
NCI
|
5R01CA105313-05
|
|
Regulation of Transcription and Cell Growth by Nkx3.1
|
HOROWITZ, JONATHAN
|
NORTH CAROLINA STATE UNIVERSITY RALEIGH
|
NC
|
$239,012
|
|
Prostate Cancer
|
NCI
|
5R01CA112250-04
|
|
Targeting Akt and Bcl-2 in Prostate Cancer Prevention
|
CHEN, CHING-SHIH
|
OHIO STATE UNIVERSITY
|
OH
|
$279,963
|
|
Prostate Cancer
|
NCI
|
5R21CA127186-02
|
|
Detecting Prostate Cancer using multi-protocol 3 Tesla in vivo MRI and MRS
|
MADABHUSHI, ANANT
|
RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK
|
NJ
|
$172,913
|
|
Prostate Cancer
|
NCI
|
7U01CA084294-10
|
|
A Mouse Model for Prostate Cancer
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$1,446,104
|
|
Prostate Cancer
|
NCI
|
5R01CA114379-02
|
|
Prostate Cancer in a Black Population
|
LESKE, MCRISTINA
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
NY
|
$826,045
|
|
Prostate Cancer
|
NCI
|
5R01CA116393-04
|
|
Protein Biomarkers of Cancer Risk in Older Persons
|
LI, CHRISTOPHER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$443,168
|
|
Prostate Cancer
|
NCI
|
5R01CA080153-09
|
|
Endothelin mechanisms in metastatic prostate cancer pain
|
STRICHARTZ, GARY
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$397,127
|
|
Prostate Cancer
|
NCI
|
5R01CA101034-04
|
|
Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids
|
HALPERIN, JOSE
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$536,186
|
|
Prostate Cancer
|
NCI
|
5R01CA108890-04
|
|
Role of Zinc in Prostate Carcinogenesis
|
KOLENKO, VLADIMIR
|
FOX CHASE CANCER CENTER
|
PA
|
$284,831
|
|
Prostate Cancer
|
NCI
|
5R01CA122906-02
|
|
Dietary histone deactylase inhibitors in prostate cancer prevention
|
HO, EMILY
|
OREGON STATE UNIVERSITY
|
OR
|
$335,954
|
|
Prostate Cancer
|
NCI
|
5R01CA085912-09
|
|
Functional Analysis of the PTEN Tumor Suppressor Protein
|
GARRAWAY, LEVI
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$266,257
|
|
Prostate Cancer
|
NCI
|
5R01CA102365-05
|
|
Invasion and metastasis in prostate cancer
|
VASIOUKHIN, VALERI
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$298,277
|
|
Prostate Cancer
|
NCI
|
5R01CA106584-04
|
|
Role of hyaluronan matrix in prostate cancer progression
|
SIMPSON, MELANIE
|
UNIVERSITY OF NEBRASKA LINCOLN
|
NE
|
$205,583
|
|
Prostate Cancer
|
NCI
|
5R01CA111479-04
|
|
Bone Metastasis Factor-1 in Prostate Cancer/Bone Interaction
|
LIN, SUE-HWA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$254,494
|
|
Prostate Cancer
|
NCI
|
5R03CA128475-02
|
|
Investigating intervention opportunities for prostate cancer patients and partner
|
COON, DAVID
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
AZ
|
$73,701
|
|
Prostate Cancer
|
NCI
|
5R01CA107575-05
|
|
Anoikis Effect by Quinazolines on Prostate Growth
|
KYPRIANOU, NATASHA
|
UNIVERSITY OF KENTUCKY
|
KY
|
$226,443
|
|
Prostate Cancer
|
NCI
|
5R01CA107693-05
|
|
Diet, Endocrine-Immune Interactions & Prostate Cancer
|
BRAY, TAMMY
|
OREGON STATE UNIVERSITY
|
OR
|
$242,340
|
|
Prostate Cancer
|
NCI
|
5R01CA108646-05
|
|
TGFB Signals in Prostate Stromal-Epithelial Interactions
|
BHOWMICK, NEIL
|
VANDERBILT UNIVERSITY
|
TN
|
$264,158
|
|
Prostate Cancer
|
NCI
|
5R01CA065435-10
|
|
QUALITY RESEARCH IN RADIATION ONCOLOGY: ACR PCS
|
WILSON, JESSE
|
AMERICAN COLLEGE OF RADIOLOGY
|
VA
|
$740,839
|
|
Prostate Cancer
|
NCI
|
5R01CA077789-10
|
|
Phase III Trial of Selenium for Prostate Cancer Prevention
|
AHMANN, FREDERICK
|
UNIVERSITY OF ARIZONA
|
AZ
|
$588,097
|
|
Prostate Cancer
|
NCI
|
5R01CA115498-04
|
|
Prevention of Prostate Cancer by Sulforaphane
|
SINGH, SHIVENDRA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$276,968
|
|
Prostate Cancer
|
NCI
|
5R01CA111803-02
|
|
Targeting AR-NCoR Interaction in Prostate Cancer
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$323,000
|
|
Prostate Cancer
|
NCI
|
5U01CA084244-10
|
|
Identification of epithelial tumor susceptibility genes
|
BALMAIN, ALLAN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$1,013,657
|
|
Prostate Cancer
|
NCI
|
5R01CA109038-04
|
|
Elucidating the somatic genetics of prostate cancer
|
MEYERSON, MATTHEW
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$432,151
|
|
Prostate Cancer
|
NCI
|
5R03CA127415-02
|
|
Regulation of androgen metabolism by the nuclear receptor CAR
|
HUANG, WENDONG
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$84,500
|
|
Prostate Cancer
|
NICHD
|
5R01HD048843-03
|
|
Studies on the Eppin family of proteins on chromosome 20
|
O'RAND, MICHAEL
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$288,281
|
|
Prostate Cancer
|
NIGMS
|
5R01GM058639-09
|
|
Pathways of Nucleocytoplasmic Transport
|
PASCHAL, BRYCE
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$259,082
|
|
Prostate Cancer
|
NCI
|
5R01CA108675-05
|
|
AR intracellular trafficking in prostate cancer
|
WANG, ZHOU
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$247,682
|
|
Prostate Cancer
|
NIDDK
|
5R01DK056238-07
|
|
The Shh-Gli Pathway Regulates Prostate Growth
|
BUSHMAN, WADE
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$286,759
|
|
Prostate Cancer
|
NCI
|
5R03CA128081-02
|
|
Detecting pre-cancerous lesions from high resolution prostate MRI
|
MADABHUSHI, ANANT
|
RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK
|
NJ
|
$77,250
|
|
Prostate Cancer
|
NCI
|
5R01CA079596-10
|
|
Genetic Analysis of Hereditary Prostate Cancer Families
|
COONEY, KATHLEEN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$297,013
|
|
Prostate Cancer
|
NCI
|
5R01CA119125-03
|
|
Resistance and Response Mechanisms to Prostate Cancer Therapy
|
BEER, TOMASZ
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$340,148
|
|
Prostate Cancer
|
NCI
|
5R01CA102139-05
|
|
Genetically Engineered Viruses for Prostate Cancer Therapy
|
MARTUZA, ROBERT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$340,161
|
|
Prostate Cancer
|
NIDDK
|
5U01DK063778-06
|
|
ALTERNATIVE THERAPIES FOR BENIGN PROSTATIC SYMPTOMS
|
NASLUND, MICHAEL
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$198,821
|
|
Prostate Cancer
|
NIDDK
|
5U01DK063835-06
|
|
Alternate Therapies for Benign Prostate Symptoms
|
ROEHRBORN, CLAUS
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$188,379
|
|
Prostate Cancer
|
NCI
|
5R01CA106504-04
|
|
Molecular Mechanisms of Hormone-independence of Prostate Cancer
|
QIU, YUN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$250,280
|
|
Prostate Cancer
|
NCI
|
5R01CA106402-05
|
|
Protein Microarrays for the Humoral Response in Cancer
|
LUBMAN, DAVID
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$225,622
|
|
Prostate Cancer
|
NCI
|
5R01CA118218-02
|
|
Replicative Adenovirus and Anti-angiogenic Therapy
|
KAO, CHINGHAI
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$287,850
|
|
Prostate Cancer
|
NCI
|
5R01CA078809-10
|
|
Green Tea in Chemoprevention of Prostate Cancer
|
MUKHTAR, HASAN
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$241,431
|
|
Prostate Cancer
|
NCI
|
5R01CA111966-04
|
|
Loss of Nkx3.1-an Initiating Event in Prostate Cancer
|
MILBRANDT, JEFFREY
|
WASHINGTON UNIVERSITY
|
MO
|
$284,645
|
|
Prostate Cancer
|
NCI
|
5R01CA083940-08
|
|
PTH-related peptide and vit D in prostate cancer growth
|
FALZON, MIRIAM
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$225,501
|
|
Prostate Cancer
|
NCI
|
5R01CA084202-08
|
|
Role of CEACAM1 in Epithelial Cell Polarization
|
SHIVELY, JOHN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$404,273
|
|
Prostate Cancer
|
NCI
|
5R01CA116658-04
|
|
Regulation of Cell Survival and Tumor Progression by Akt
|
RANGNEKAR, VIVEK
|
UNIVERSITY OF KENTUCKY
|
KY
|
$246,909
|
|
Prostate Cancer
|
NCI
|
5U01CA114583-04
|
|
CNP for Older Underserved African American Adults
|
ALBRECHT, TERRANCE
|
WAYNE STATE UNIVERSITY
|
MI
|
$473,207
|
|
Prostate Cancer
|
NIDDK
|
5R01DK040890-18
|
|
Development Estrogenization of the Rat Prostate Gland
|
PRINS, GAIL
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$273,654
|
|
Prostate Cancer
|
NCI
|
5U10CA016116-35
|
|
Eastern Cooperative Oncology Group
|
FORASTIERE, ARLENE
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$279,595
|
|
Prostate Cancer
|
NCI
|
5R01CA116815-04
|
|
Apoptotic effect of zinc in targeting prostate cancer
|
FENG, PEI
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$247,193
|
|
Prostate Cancer
|
NCI
|
5R01CA027440-29
|
|
ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCER
|
BRODIE, ANGELA
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$316,811
|
|
Prostate Cancer
|
NCI
|
5R01CA112532-03
|
|
Hormone-induced inflammation and prostate cancer
|
HO, SHUK-MEI
|
UNIVERSITY OF CINCINNATI
|
OH
|
$264,562
|
|
Prostate Cancer
|
NCI
|
5R01CA015776-29
|
|
Prostatic Differentiation and Sex Hormone Metabolism
|
HO, SHUK-MEI
|
UNIVERSITY OF CINCINNATI
|
OH
|
$294,731
|
|
Prostate Cancer
|
NCI
|
5R01CA074042-11
|
|
Tissue Specific Gene Therapy for Human Prostate Cancer
|
KAO, CHINGHAI
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$265,033
|
|
Prostate Cancer
|
NCI
|
5U01CA084296-10
|
|
Mouse Models of Prostate Cancer
|
GREENBERG, NORMAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$1,159,972
|
|
Prostate Cancer
|
NCI
|
5U10CA021076-33
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
|
KAHL, BRAD
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$610,603
|
|
Prostate Cancer
|
NIEHS
|
5R01ES011126-07
|
|
A Nested Case-Control Study of Prostate Carcinogenesis
|
RYBICKI, BENJAMIN
|
HENRY FORD HEALTH SYSTEM
|
MI
|
$588,386
|
|
Prostate Cancer
|
NIA
|
1SC1AG033407-01A1
|
|
Role of Follistatin during Androgen Regulation of Body Composition
|
SINGH, RAJAN
|
CHARLES R. DREW UNIVERSITY OF MED & SCI
|
CA
|
$282,000
|
|
Prostate Cancer
|
NCI
|
5R01CA087921-08
|
|
Overexpression of ubiquitin E3 ligase WWP1 as an oncogenic factor in the prostate
|
DONG, JIN-TANG
|
EMORY UNIVERSITY
|
GA
|
$240,227
|
|
Prostate Cancer
|
NCI
|
5R01CA101113-05
|
|
Vitamin D Status and Prostate Cancer
|
FLEET, JAMES
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
IN
|
$315,551
|
|
Prostate Cancer
|
NCI
|
5R01CA106653-03
|
|
PMEPA1 Function and Expression in Prostate Cancer
|
SRIVASTAVA, SHIV
|
HENRY M. JACKSON FDN FOR THE ADV MIL/MED
|
MD
|
$156,800
|
|
Prostate Cancer
|
NCI
|
5R01CA109246-04
|
|
MR Guided Focused Ultrasound Surgery for Prostate Cancer
|
TEMPANY, CLARE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$478,840
|
|
Prostate Cancer
|
NIDDK
|
5K23DK071262-04
|
|
Prostate Cancer Detection by Molecular Urinalysis
|
PAVLOVICH, CHRISTIAN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$135,230
|
|
Prostate Cancer
|
NCI
|
5R01CA084950-09
|
|
Molecular Epidemiology of Prostate Cancer in Tobagonians
|
BUNKER, CLAREANN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$469,692
|
|
Prostate Cancer
|
NCI
|
5R01CA115527-02
|
|
Targeting Nanoparticle DNA Delivery to Prostate Tumors
|
SAWICKI, JANET
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
PA
|
$310,762
|
|
Prostate Cancer
|
NIEHS
|
5R01ES013557-03
|
|
BIOSENSOR ARRAYS BASED ON SINGLE WALL CARBON NANOTUBES
|
RUSLING, JAMES
|
UNIVERSITY OF CONNECTICUT STORRS
|
CT
|
$267,584
|
|
Prostate Cancer
|
NIDCR
|
5F30DE018308-02
|
|
The Role of Osteopontin in Cancer Progression and Bone Metastasis
|
ROBERTSON, BRIAN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$32,780
|
|
Prostate Cancer
|
NIDDK
|
5R01DK068503-04
|
|
BRK/Sik Tyrosine Kinase Signaling in the Prostate
|
TYNER, ANGELA
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$263,020
|
|
Prostate Cancer
|
NCI
|
5R21CA120896-02
|
|
Targeted, Tailored and Timely (T3) Symptom Management for Prostate Cancer
|
BECK, SUSAN
|
UNIVERSITY OF UTAH
|
UT
|
$142,851
|
|
Prostate Cancer
|
NCI
|
5R01CA112632-04
|
|
Tomato-Soy Juice for Prostate Cancer
|
CLINTON, STEVEN
|
OHIO STATE UNIVERSITY
|
OH
|
$279,963
|
|
Prostate Cancer
|
NCI
|
1R01CA132803-01
|
|
LHRH Agonist Therapy and Cognitive Functioning in Men with Prostate Cancer
|
JACOBSEN, PAUL
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$425,501
|
|
Prostate Cancer
|
NIBIB
|
5R01EB007171-04
|
|
Polymers for Targeted Delivery of Angiogenic Inhibitors
|
GHANDEHARI, HAMID
|
UNIVERSITY OF UTAH
|
UT
|
$241,733
|
|
Prostate Cancer
|
NCI
|
5R01CA111613-04
|
|
FDG PET-CT in Metastatic Prostate Cancer
|
JADVAR, HOSSEIN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$505,093
|
|
Prostate Cancer
|
NCI
|
5K07CA106730-04
|
|
Prostate cancer and genes of the one-carbon cycle
|
ZEIGLER-JOHNSON, CHARNITA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$138,672
|
|
Prostate Cancer
|
NCI
|
5R01CA080122-10
|
|
Genetic Epidemiology of Prostate Cancer
|
STANFORD, JANET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$423,798
|
|
Prostate Cancer
|
NCI
|
1R01CA132831-01
|
|
DOUBLE-TARGETED MACROMOLECULAR THERAPEUTICS FOR THE TREATMENT OF PROSTATE CANCER
|
KOPECEK, JINDRICH
|
UNIVERSITY OF UTAH
|
UT
|
$311,769
|
|
Prostate Cancer
|
NCI
|
1R43CA132852-01
|
|
Multiplexed biomarker panels for early detection of prostate cancer
|
MATHEW, ANU
|
MESO SCALE DIAGNOSTICS, LLC
|
MD
|
$129,673
|
|
Prostate Cancer
|
NCI
|
1R43CA132841-01
|
|
Array-assisted Insertional Mutagenesis Platform for Forward Genetics of Cancer
|
CHENCHIK, ALEX
|
CELLECTA, INC.
|
CA
|
$92,940
|
|
Prostate Cancer
|
NIDDK
|
5R01DK076763-02
|
|
Prolactin receptor signaling of prolactin metabolic effects in the prostate
|
FRANKLIN, RENTY
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$298,337
|
|
Prostate Cancer
|
NCI
|
5R01CA118003-03
|
|
US Prostate Cancer Detection with Dutasteride Pretreatment
|
HALPERN, ETHAN
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$368,892
|
|
Prostate Cancer
|
NCI
|
5K24CA121990-02
|
|
Midcareer Investigator Award
|
SMITH, MATTHEW
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$191,090
|
|
Prostate Cancer
|
NCI
|
1R01CA133458-01
|
|
Integrative Metabolomics of Prostate Cancer Progression
|
SREEKUMAR, ARUN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$315,400
|
|
Prostate Cancer
|
NCI
|
5K22CA118421-03
|
|
Selenium genetic variation in selenoenzymes and prostate cancer
|
PETERS, ULRIKE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$156,006
|
|
Prostate Cancer
|
NCI
|
5R01CA122332-02
|
|
Role of the tumor suppressor KLF6 in prostate cancer
|
MARTIGNETTI, JOHN
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$315,400
|
|
Prostate Cancer
|
NCI
|
5R01CA106296-05
|
|
Chemopreventive Effect of NSAIDs Against Prostate Cancer
|
NARAYANAN, BHAGAVATHI
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$295,647
|
|
Prostate Cancer
|
NCI
|
5K01CA114253-03
|
|
Regulation of Prostate Cancer Growth by PPARg Ligands
|
STEWART, LAMONICA
|
MEHARRY MEDICAL COLLEGE
|
TN
|
$150,468
|
|
Prostate Cancer
|
NCI
|
5R01CA109339-05
|
|
A Transgenic Model for Prostate Tumor Immunity
|
ADLER, ADAM
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
CT
|
$281,848
|
|
Prostate Cancer
|
NIBIB
|
5R21EB006466-02
|
|
Computer-Aided Analysis of Histopathology Images of Prostate Cancer
|
JIANG, YULEI
|
UNIVERSITY OF CHICAGO
|
IL
|
$187,267
|
|
Prostate Cancer
|
NCI
|
5R03CA128028-02
|
|
A Pharmacogenetic approach to prostate cancer susceptibility
|
KIDD, LA CREIS
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$74,000
|
|
Prostate Cancer
|
NCI
|
5K08CA122833-02
|
|
High-resolution genome-wide mapping of structural mutations in prostate cancer
|
BEROUKHIM, RAMEEN
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$139,320
|
|
Prostate Cancer
|
NCI
|
5R21CA126786-02
|
|
Genetics of Germline Gene Expression Phenotype in Aggressive Prostate Cancer
|
WANG, LIANG
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$181,320
|
|
Prostate Cancer
|
NCI
|
5R01CA105435-06
|
|
Sodium Channel Blockers as Inhibitors of Prostate Cancer
|
BROWN, MILTON
|
GEORGETOWN UNIVERSITY
|
DC
|
$328,773
|
|
Prostate Cancer
|
NCI
|
5R01CA092447-07
|
|
Southern Community Cohort Study
|
BLOT, WILLIAM
|
VANDERBILT UNIVERSITY
|
TN
|
$5,456,051
|
|
Prostate Cancer
|
NCI
|
5R01CA089202-08
|
|
Prostate carcinogenesis and PKC signaling
|
KAZANIETZ, MARCELO
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$284,363
|
|
Prostate Cancer
|
NCI
|
1R21CA133338-01
|
|
Imaging Prostate Cancer with SQUID-Detected Microtesla MRI
|
CLARKE, JOHN
|
UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
|
CA
|
$208,756
|
|
Prostate Cancer
|
NCI
|
5R01CA113580-03
|
|
Stat5 in Progression of Prostate Cancer
|
NEVALAINEN, MARJA
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$267,147
|
|
Prostate Cancer
|
NCI
|
1R21CA133634-01
|
|
Prostate Fusion Gene Variants as a Cancer Biomarker
|
LIU, YU-TSUENG
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$173,813
|
|
Prostate Cancer
|
NCI
|
5R01CA101023-05
|
|
Vitamin D and Soy Isoflavone Inhibition of Prostate
|
CRAMER, SCOTT
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$251,038
|
|
Prostate Cancer
|
NCI
|
5F31CA123703-03
|
|
Identification of Prostate Stem Cells in the Mouse
|
SCOTLAND, KYMORA
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$44,289
|
|
Prostate Cancer
|
NIDDK
|
1K08DK081019-01
|
|
Roles for Phospholipase A2 Signaling in Prostate Development
|
SCHAEFFER, EDWARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$157,248
|
|
Prostate Cancer
|
NCI
|
5R01CA121153-02
|
|
Development of Highly Targeted, Imageable Adenoviral Vectors for Prostate Cancer
|
RODRIGUEZ, RONALD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$311,600
|
|
Prostate Cancer
|
NCI
|
5R01CA105055-05
|
|
Association of inflammatory genes and prostate cancer
|
XU, JIANFENG
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$441,199
|
|
Prostate Cancer
|
NCI
|
5R01CA118682-02
|
|
The Functions of Affect in Treatment Decisions of Rising PSA Patients
|
DIEFENBACH, MICHAEL
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$330,373
|
|
Prostate Cancer
|
NCI
|
1R21CA133456-01
|
|
Chitosan-plasmid DNA nanoplexes and adenoviruses as prostate cancer vaccines
|
SALEM, ALIASGER
|
UNIVERSITY OF IOWA
|
IA
|
$168,750
|
|
Prostate Cancer
|
NCI
|
5R01CA111470-03
|
|
Genistein and Prostate Cancer
|
DAHIYA, RAJVIR
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
CA
|
$271,628
|
|
Prostate Cancer
|
NCI
|
5R01CA108512-05
|
|
Mechanisms of Prostate Cancer Chemoprevention by Apigenin
|
GUPTA, SANJAY
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$228,488
|
|
Prostate Cancer
|
NCI
|
1R21CA133618-01
|
|
Targeted Ceramic Nanovectors for Simultaneous Therapy and Imaging of Cancer
|
DEY, SANDWIP
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
AZ
|
$231,517
|
|
Prostate Cancer
|
NCI
|
5R01CA085142-09
|
|
Glucocorticoids & Vitamin D: Role in Antitumor Effects
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$377,384
|
|
Prostate Cancer
|
NCI
|
5R01CA115484-04
|
|
CaP Metastasis Biomarkers: Validation/Genomics/Biology
|
COLLINS, COLIN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$283,708
|
|
Prostate Cancer
|
NCI
|
5R01CA122060-02
|
|
Phase II Clinical Trial of Polyphenon E in Prostate Cancer
|
KUMAR, NAGI
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$689,729
|
|
Prostate Cancer
|
NCI
|
5R01CA111288-03
|
|
Enabling Technologies for MRI-Guided Prostate Interventions
|
TEMPANY, CLARE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$731,599
|
|
Prostate Cancer
|
NCI
|
5R03CA123623-02
|
|
Polybrominated Biphenyls and Cancer Risk
|
ROSENBLATT, KARIN
|
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN
|
IL
|
$74,509
|
|
Prostate Cancer
|
NCI
|
5R01CA123194-02
|
|
Agents for Specific NMR and SQUID Imaging of Prostate Cancer
|
SILLERUD, LAUREL
|
UNIVERSITY OF NEW MEXICO
|
NM
|
$443,966
|
|
Prostate Cancer
|
RMAP
|
1R03MH083258-01
|
|
A High-Throughput Screen to Identify Small Molecule Compounds That Augment
|
PASSER, BRENT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$24,999
|
|
Prostate Cancer
|
NCI
|
5R01CA125661-02
|
|
Regulator of G-protein Signaling (RGS) Proteins in Prostate Cancer
|
TU, YAPING
|
CREIGHTON UNIVERSITY
|
NE
|
$250,118
|
|
Prostate Cancer
|
NCI
|
5R21CA131988-02
|
|
Regulation of AR function by NOS
|
DAAKA, YEHIA
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
GA
|
$176,400
|
|
